Please assess the completion status of the following clinical trial:

Trial Title: Safety and Immunogenicity (Non-inferiority) of a Purified Chick Embryo Cell Vaccine Vaccine Administered in Two Different Schedules (Conventional Versus Abbreviated Schedule)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female subjects 18-50 years of age who:~* are in good health at the time of entry into the study as determined by medical history, physical examination and clinical judgment of the investigator;~* volunteer for the simulated post-exposure vaccination courses and blood draws;~* have given a written informed consent; informed consent must be obtained for all the subjects before enrolment in the study;~* are available for all the visits scheduled in the study.~Exclusion Criteria:~* Subjects with the below criteria were excluded:~* pregnancy or unwillingness to practice acceptable contraception during participation in the study;~* a history of rabies immunization;~* a significant acute or chronic infectious disease that may impact the subject's safety and /or immunogenicity in the Investigators opinion at the time of enrolment;~* fever ≥ 38.0°C (axillary) or/and significant acute or chronic infection requiring systemic antibiotic or antiviral therapy within the past 7 days before enrolment;~* treatment with corticosteroids, immunosuppressive or antimalaria drugs during the two month period before enrolment;~* administration of any vaccine within the past 14 days before enrolment;~* known/suspected immunodeficiency, or autoimmune disease, or any immunologic disorder;~* history of allergy to egg protein;~* known hypersensitivity to neomycin, tetracycline, amphotericin-B, or any other vaccine component;~* treatment with parenteral immunoglobulin preparation, blood products, and/or plasma derivatives within the past 3 months;~* mental condition rendering the subject unable to understand the nature, scope and consequences of the study;~* participation in any other investigational trial within the past 3 months before enrolment;~* planned surgery during the study period;~* intention to leave the area of the study site before the end of study period;~* any condition which, in the opinion of the investigator, might interfere with the evaluation of the study objective.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- Zagreb (2-1-1) (Type: EXPERIMENTAL): Rabies PCEC vaccine was applied according Zagreb schedule with 2 vaccinations on day 0, 1 vaccination on day 7 and day 21, respectively
- Essen (1-1-1-1-1) (Type: ACTIVE_COMPARATOR): Rabies PCEC vaccine was applied according Essen schedule, i.e. 1 vaccination on day 0, day 3, day 7, day 14 and day 28, respectively.

Based on this trial design, predict the completion outcome and termination type (if applicable).